Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2445-2456

  Sundstrøm, Terje ^a,b   Daphu, Inderjit ^a   Wendelbo, Ingvild ^a   Hodneland, Erlend ^a   Lundervold, Arvid ^a   Immervoll, Heike ^c   Skaftnesmo, Kai Ove ^a   Babic, Michal ^d   Jendelova, Pavla ^e,f   Sykova, Eva ^e,f   Lund Johansen, Morten ^a,b   Bjerkvig, Rolf ^a,g   Thorsen, Frits ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Alesund Hospital   (Norway)

^d Institute of Macromolecular Chemistry   (Norway)

^e INSTITUTE OF MATHEMATICS   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g NorLux Neuro Oncology Laboratory   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOMATION; BRAIN METASTASIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL LABELING; CELL MIGRATION; CELL TRACKING; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEART VENTRICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; VALIDATION PROCESS;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CELL TRACKING; CYTOPLASM; DISEASE MODELS, ANIMAL; FEMALE; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MELANOMA; MICE; STAINING AND LABELING; TIME FACTORS; TUMOR BURDEN; WOUND HEALING;

EID: 84876965552     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3514     Document Type: Article

References (50)

1. Fidler IJ, Schackert G, Zhang RD, Radinsky R, Fujimaki T. The biology of melanoma brain metastasis. Cancer Metastasis Rev 1999;18: 387-400.
2. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293-300.
3. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
4. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012;13: 459-65.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
6. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61.
7. Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: Opportunities in basic and translational research. Cancer Res 2009;69:6015-20.
8. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: Unraveling mechanisms and future treatment options. Cancer Res 2011;71:7137-40.
9. Bos PD, Nguyen DX, Massague J. Modeling metastasis in the mouse. Curr Opin Pharmacol 2010;10:571-7.
10. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
11. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007;13:1656-62.
12. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nat Rev Clin Oncol 2012;9: 215-22.
13. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al. Brain metastases: Pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-22.
14. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
15. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 2011;10:328-9.
16. Arrowsmith J. Trial watch: Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011;10:87.
17. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700.
18. Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong? Nat Rev Clin Oncol 2011;22:2007-13.
19. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
20. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
21. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-63.
22. Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, et al. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 2012;13:e205-11.
23. Conley FK. Development of a metastatic brain tumor model in mice. Cancer Res 1979;39:1001-7.
24. Cranmer LD, Trevor KT, Bandlamuri S, Hersh EM. Rodent models of brain metastasis in melanoma. Melanoma Res 2005;15:325-56.
25. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351-4.
26. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-60.
27. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
28. Fidler IJ. Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-20-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
29. Basse P, Hokland P, Heron I, Hokland M. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: Role of natural killer cells. J Natl Cancer Inst 1988;80:657-65.
30. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006;56:1001-10.
31. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol 2011;8:677-88.
32. Arbab AS, Janic B, Haller J, Pawelczyk E, Liu W, Frank JA. In vivo cellular imaging for translational medical research. Curr Med Imaging Rev 2009;5:19-38.
33. Bulte JW. In vivo MRI cell tracking: Clinical studies. AJR Am J Roentgenol 2009;193:314-25.
34. Rosen JE, Chan L, Shieh DB, Gu FX. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine 2011;8: 275-90.
35. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006;55:23-9.
36. Cromer Berman SM, Walczak P, Bulte JW. Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip RevNanomed Nanobiotechnol 2011;3:343-55.
37. Liu W, Frank JA. Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol 2009;70:258-64.
38. Rad AM, Arbab AS, Iskander AS, Jiang Q, Soltanian-Zadeh H. Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI. J Magn Reson Imaging 2007;26:366-74.
39. Babic M, Horak D, Trchova M, Jendelova P, Glogarova K, Lesny P, et al. Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem 2008;19:740-50.
40. Novotna B, Jendelova P, Kapcalova M, Rossner P, Turnovcova K, Bagryantseva Y, et al. Oxidativedamage to biological macromolecules in human bone marrow mesenchymal stromal cells labeled with various types of iron oxide nanoparticles. Toxicol Lett 2012;210:53-63.
41. Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, Mørk S, et al. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol 2011;37:189-205.
42. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
43. Arguello F, Furlanetto RW, Baggs RB, Graves BT, Harwell SE, Cohen HJ, et al. Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/ Sld and W/Wv). Cancer Res 1992;52:2304-9.
44. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 2008;68:4500-5.
45. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.
46. Kiowski G, Biedermann T, Widmer DS, Civenni G, Burger C, Dummer R, et al. Engineering melanoma progression in a humanized environment in vivo. J Invest Dermatol 2012;132:144-53.
47. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
48. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13.
49. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biol Ther 2003;2: S134-9.
50. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2012;2:86-102.